Multi-Omics Integration for the Design of Novel Therapies and the Identification of Novel Biomarkers

Ivanisevic, Tonci; Sewduth, Raj N.

doi:10.3390/proteomes11040034

Cited by 28 publications

(8 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One important area of proteomics is the clinical study of disease (especially cancer) biomarkers and potential drug targets. In the past 10 years, proteomics research has made significant progress [ 80 , 81 , 82 , 83 ]. To find specific biomarkers, proteomics researchers usually try to analyze the diversity of the human proteome, which includes multiple proteoforms.…”

Section: Clinical Aspects Of Proteoformsmentioning

confidence: 99%

Puzzle of Proteoform Variety—Where Is a Key?

Naryzhny

2024

Proteomes

View full text Add to dashboard Cite

One of the human proteome puzzles is an imbalance between the theoretically calculated and experimentally measured amounts of proteoforms. Considering the possibility of combinations of different post-translational modifications (PTMs), the quantity of possible proteoforms is huge. An estimation gives more than a million different proteoforms in each cell type. But, it seems that there is strict control over the production and maintenance of PTMs. Although the potential complexity of proteoforms due to PTMs is tremendous, available information indicates that only a small part of it is being implemented. As a result, a protein could have many proteoforms according to the number of modification sites, but because of different systems of personal regulation, the profile of PTMs for a given protein in each organism is slightly different.

show abstract

Section: Clinical Aspects Of Proteoformsmentioning

confidence: 99%

Puzzle of Proteoform Variety—Where Is a Key?

Naryzhny

2024

Proteomes

View full text Add to dashboard Cite

show abstract

“…Despite the potential of multi-omics to identify targeted therapies, some patients may benefit more than others due to distinct genetic and molecular profiles within a single tumour. [29] This heterogeneity has increased the ethical and legal challenges characteristic of interdisciplinary research that cuts across different healthcare domains. Medical scientists and clinicians share the responsibility for the introduction of clinically relevant genome-scale and targeted multi-gene NGS panels into the healthcare system, with the aim to transform standard cancer care into precision oncology.…”

Section: Bridging Knowledge Gaps In Molecular Pathology Applied In On...mentioning

confidence: 99%

Navigating ethical challenges of integrating genomic medicine into clinical practice: Maximising beneficence in precision oncology

Kotze,

Grant,

Van der Merwe

et al. 2024

S Afr J Bioethics Law

View full text Add to dashboard Cite

The development of gene expression profiling and next-generation sequencing technologies have steered oncogenomics to the forefront of precision medicine. This created a need for harmonious cooperation between clinicians and researchers to increase access to precision oncology, despite multiple implementation challenges being encountered. The aim is to apply personalised treatment strategies early in cancer management, targeting tumour subtypes and actionable gene variants within the individual’s broader clinical risk profile and wellbeing. A knowledge-generating database linked to the South African Medical Research Council’s Genomic Centre has been created for the application of personalised medicine, using an integrated service and research approach. Insights gained from patient experiences related to tumour heterogeneity, access to targeted therapies and incidental findings of pathogenic germline variants in tumour DNA, provided practice-changing evidence for the implementation of a cost-minimisation pathology-supported genetic testing strategy. Integrating clinical care with genomic research through data sharing advances personalised medicine and maximises precision oncology benefits.

show abstract

“…Integrating metabolomics with other 'omics' technologies: The combination with omics such as genomics, proteomics, and transcriptomics offers a comprehensive and holistic approach to understanding the biological impact of drugs [89,90]. This multi-omics integration enables a deeper insight into the systemic effects of drug-induced changes, providing a more complete picture of the molecular landscape.…”

Section: Artificial Intelligence In Metabolomicsmentioning

confidence: 99%

Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends

Sillé,

Hartung

2024

Metabolites

View full text Add to dashboard Cite

Metabolomics is emerging as a powerful systems biology approach for improving preclinical drug safety assessment. This review discusses current applications and future trends of metabolomics in toxicology and drug development. Metabolomics can elucidate adverse outcome pathways by detecting endogenous biochemical alterations underlying toxicity mechanisms. Furthermore, metabolomics enables better characterization of human environmental exposures and their influence on disease pathogenesis. Metabolomics approaches are being increasingly incorporated into toxicology studies and safety pharmacology evaluations to gain mechanistic insights and identify early biomarkers of toxicity. However, realizing the full potential of metabolomics in regulatory decision making requires a robust demonstration of reliability through quality assurance practices, reference materials, and interlaboratory studies. Overall, metabolomics shows great promise in strengthening the mechanistic understanding of toxicity, enhancing routine safety screening, and transforming exposure and risk assessment paradigms. Integration of metabolomics with computational, in vitro, and personalized medicine innovations will shape future applications in predictive toxicology.

show abstract

Multi-Omics Integration for the Design of Novel Therapies and the Identification of Novel Biomarkers

Cited by 28 publications

References 68 publications

Puzzle of Proteoform Variety—Where Is a Key?

Puzzle of Proteoform Variety—Where Is a Key?

Navigating ethical challenges of integrating genomic medicine into clinical practice: Maximising beneficence in precision oncology

Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends

Contact Info

Product

Resources

About